Refractory indolent B cell non-hodgkin lymphoma
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB06769 | Bendamustine | An antineoplastic agent used for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed following rituximab therapy. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB06769 | Bendamustine | Cytochrome P450 1A2 | enzyme |
| Drug | Drug Name | Phase | Status | Count |
|---|